Phillip A. Levin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Phillip A. Levin has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
- Nikolay Sergeevich Grachev
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Health of the Russian Federation
4 shared publications - Pavel A. Zharkov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
4 shared publications - Alexey Aleksandrovich Maschan
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Health of the Russian Federation
3 shared publications - Leyla Seymurovna Namazova-Baranova
Russian Scientific Surgery Center named after Academician B.V. Petrovskiy with the Russian Academy of Sciences, Moscow, Russia
3 shared publications - Marina V. Gaskova
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
3 shared publications Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
3 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (3) , 14-21
Learning curve for laparoscopic liver resections in children: a risk-adjusted cumulative summation analysis. Single-center experience
Objective – to evaluate the learning curve of laparoscopic liver resections in children using the risk-associated cumulative summary analysis (RA-CUSUM) method with one surgeon experience in performing these open operations in adults and children. Materials and methods. A database consisting of 52 patients that were operated in 2018-2024 on the basis of one center was analyzed. Due to the rarity of liver tumors between children, the study included patients with liver diseases of various etiologies – benign and malignant neoplasms, metastatic lesions. The learning curves were analyzed using approximation methods, exponential function of the ratio of surgery time to the experience gained by the surgeon, and the method of RA-CUSUM. To calculate the risk of surgical intervention we’ve used a difficulty scoring system, that was developed and published by a team of authors. The time of the operation was compared, and the criteria for failure were pathological bleeding that led to the conversion. Results. Evaluating the results relative to the time of surgical interventions, it was found that the maximum value of the approximating function is achieved at approximately 21 operations performed, the proportion of observations (coefficient of determination) explained by this model is R2 = 90%. According to the results of the exponential function construction, the regression coefficient shows that with each new operation, its time decreases by an average of 1.39%, and after 10 operations by an average of 13.04%. The graph constructed by the method of RA-CUSUM gave a stable decline, starting with the 24th operation performed. Conclusion. As the number of laparoscopic liver resections increases, the time of surgery and the frequency of pathological bleeding that leads to conversion significantly decrease. A surgeon with experience in open liver resections will need about 20–25 operations to learn how to perform laparoscopic liver resections in children. A difficulty scoring system, that was developed in our center for predicting and assessing preoperative risk, has proved its effectiveness.
- 19 August 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (3) , 14-21
Open AccessLearning curve for laparoscopic liver resections in children: a risk-adjusted cumulative summation analysis. Single-center experience
Objective – to evaluate the learning curve of laparoscopic liver resections in children using the risk-associated cumulative summary analysis (RA-CUSUM) method with one surgeon experience in performing these open operations in adults and children. Materials and methods. A database consisting of 52 patients that were operated in 2018-2024 on the basis of one center was analyzed. Due to the rarity of liver tumors between children, the study included patients with liver diseases of various etiologies – benign and malignant neoplasms, metastatic lesions. The learning curves were analyzed using approximation methods, exponential function of the ratio of surgery time to the experience gained by the surgeon, and the method of RA-CUSUM. To calculate the risk of surgical intervention we’ve used a difficulty scoring system, that was developed and published by a team of authors. The time of the operation was compared, and the criteria for failure were pathological bleeding that led to the conversion. Results. Evaluating the results relative to the time of surgical interventions, it was found that the maximum value of the approximating function is achieved at approximately 21 operations performed, the proportion of observations (coefficient of determination) explained by this model is R2 = 90%. According to the results of the exponential function construction, the regression coefficient shows that with each new operation, its time decreases by an average of 1.39%, and after 10 operations by an average of 13.04%. The graph constructed by the method of RA-CUSUM gave a stable decline, starting with the 24th operation performed. Conclusion. As the number of laparoscopic liver resections increases, the time of surgery and the frequency of pathological bleeding that leads to conversion significantly decrease. A surgeon with experience in open liver resections will need about 20–25 operations to learn how to perform laparoscopic liver resections in children. A difficulty scoring system, that was developed in our center for predicting and assessing preoperative risk, has proved its effectiveness.
- Open Access
- 30 June 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (2) , 83-88
Biobanking of CD45RA-depleted products: assessment of the functional status of virus-specific memory T cells during long-term cryopreservation
Introduction. The quantification and functional assessment of virus-specific T cells (VSTs) in donor cell products is an important factor for predicting immune reconstitution and planning antiviral treatment in recipients after hematopoietic stem cell transplantation. Aim: to assess the quantity and functionality of VSTs in CD45RA-depleted donor lymphocyte products after long-term cryopreservation. Materials and methods. This study included peripheral blood mononuclear cell samples obtained from 16 donors and samples of their CD45RA-depleted fractions: fresh and thawed after 2–4 weeks, 5 and 7 years of cryopreservation. The number of VSTs specific to cytomegalovirus (CMV), Epstein–Barr virus (EBV) and adenovirus (ADV) was determined by the ELISpot assay (300 000 mononuclear cells per sample). Before analysis of the CD45RA-depleted products, the cells were rested for 18 hours in CTL Test Medium. Results. CD45RA-depleted products, both before cryopreservation and after thawing without subsequent cell resting, exhibited very low detectability of VSTs, despite the high frequency of such cells in the peripheral blood of the same donors. After resting, the detectability of VSTs recovered both in fresh and thawed CD45RA-depleted samples. Cryopreservation for 5 years was associated with a marked reduction in the detectability of CMV-, EBV-, and ADV-specific cells. When the cryopreservation period extended to 7 years, a further reduction in the detectability of ADV- and EBV-specific T cells was observed; however, the level of CMV-specific T cells did not show such significant changes. Conclusion. The ELISpot assay performed on cryopreserved CD45RA-depleted samples prior to clinical use helps to assess the functional activity of pathogen-specific cells. For reliable quantification of VSTs in CD45RA-depleted products, cells should be cultured for 18 hours in serum-free medium before the ELISpot assay.
- 30 June 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (2) , 83-88
Open AccessBiobanking of CD45RA-depleted products: assessment of the functional status of virus-specific memory T cells during long-term cryopreservation
Introduction. The quantification and functional assessment of virus-specific T cells (VSTs) in donor cell products is an important factor for predicting immune reconstitution and planning antiviral treatment in recipients after hematopoietic stem cell transplantation. Aim: to assess the quantity and functionality of VSTs in CD45RA-depleted donor lymphocyte products after long-term cryopreservation. Materials and methods. This study included peripheral blood mononuclear cell samples obtained from 16 donors and samples of their CD45RA-depleted fractions: fresh and thawed after 2–4 weeks, 5 and 7 years of cryopreservation. The number of VSTs specific to cytomegalovirus (CMV), Epstein–Barr virus (EBV) and adenovirus (ADV) was determined by the ELISpot assay (300 000 mononuclear cells per sample). Before analysis of the CD45RA-depleted products, the cells were rested for 18 hours in CTL Test Medium. Results. CD45RA-depleted products, both before cryopreservation and after thawing without subsequent cell resting, exhibited very low detectability of VSTs, despite the high frequency of such cells in the peripheral blood of the same donors. After resting, the detectability of VSTs recovered both in fresh and thawed CD45RA-depleted samples. Cryopreservation for 5 years was associated with a marked reduction in the detectability of CMV-, EBV-, and ADV-specific cells. When the cryopreservation period extended to 7 years, a further reduction in the detectability of ADV- and EBV-specific T cells was observed; however, the level of CMV-specific T cells did not show such significant changes. Conclusion. The ELISpot assay performed on cryopreserved CD45RA-depleted samples prior to clinical use helps to assess the functional activity of pathogen-specific cells. For reliable quantification of VSTs in CD45RA-depleted products, cells should be cultured for 18 hours in serum-free medium before the ELISpot assay.
- Open Access
Neonatal BCG and Hepatitis B Vaccination and Incidence of Atopic Dermatitis in Children by 36 Month of Age: Results of Prospective Study
Background: The steady increase in allergic diseases among children has coincided with increased global vaccination coverage and the expansion of routine childhood immunization programs. This has contributed to the widespread belief that there is a possible link between immunoprophylaxis and allergic diseases. However, a number of scientific studies have demonstrated the protective effect of early neonatal immunization on the development of nonspecific immunological protection against infections. This is believed to be due to a shift in the immune response from the Th2 type, traditionally predominant in newborns, to the Th1 type, which reduces the risk of developing allergic diseases. Methods: This prospective cohort study analyzed the medical records of 2279 children born between 2018 and 2022 to evaluate the impact of neonatal BCG-M and hepatitis B (HepB) vaccination on the incidence of atopic dermatitis (AD) by 36 months of age. Factors analyzed included family history of allergy, cesarean section, prematurity, delayed initiation of breastfeeding, maternal antibiotic use during pregnancy, and antibiotic use in the child during the first three years of life. Results: The cumulative incidence of AD by 36 months of age was 19.9%. Timely neonatal vaccination coverage was 76.2% for BCG-M and 69.2% for HepB; by 12 months of age, these rates increased to 90.2% and 88.5%, respectively. A full-term birth demonstrated a significant protective effect (OR 0.52; 95% CI 0.30–0.93). A positive family history of allergy was the strongest predictor of AD (OR 21.49; 95% CI 14.4–32.9). Cesarean section was also significantly associated with AD (OR 1.30; 95% CI 1.01–1.65). AD incidence was comparable between vaccinated (20.5%) and non-vaccinated (17.5%) children (chi-squared with Yates’ correction, p = 0.192), indicating no statistically significant overall impact of immunization on AD risk. Conclusions: The development of AD is primarily driven by hereditary predisposition and specific perinatal factors rather than by routine immunization. These findings confirm that neonatal BCG-M and HepB vaccination does not increase the risk of AD, providing a scientific basis to address vaccine hesitancy.
Open AccessNeonatal BCG and Hepatitis B Vaccination and Incidence of Atopic Dermatitis in Children by 36 Month of Age: Results of Prospective Study
Background: The steady increase in allergic diseases among children has coincided with increased global vaccination coverage and the expansion of routine childhood immunization programs. This has contributed to the widespread belief that there is a possible link between immunoprophylaxis and allergic diseases. However, a number of scientific studies have demonstrated the protective effect of early neonatal immunization on the development of nonspecific immunological protection against infections. This is believed to be due to a shift in the immune response from the Th2 type, traditionally predominant in newborns, to the Th1 type, which reduces the risk of developing allergic diseases. Methods: This prospective cohort study analyzed the medical records of 2279 children born between 2018 and 2022 to evaluate the impact of neonatal BCG-M and hepatitis B (HepB) vaccination on the incidence of atopic dermatitis (AD) by 36 months of age. Factors analyzed included family history of allergy, cesarean section, prematurity, delayed initiation of breastfeeding, maternal antibiotic use during pregnancy, and antibiotic use in the child during the first three years of life. Results: The cumulative incidence of AD by 36 months of age was 19.9%. Timely neonatal vaccination coverage was 76.2% for BCG-M and 69.2% for HepB; by 12 months of age, these rates increased to 90.2% and 88.5%, respectively. A full-term birth demonstrated a significant protective effect (OR 0.52; 95% CI 0.30–0.93). A positive family history of allergy was the strongest predictor of AD (OR 21.49; 95% CI 14.4–32.9). Cesarean section was also significantly associated with AD (OR 1.30; 95% CI 1.01–1.65). AD incidence was comparable between vaccinated (20.5%) and non-vaccinated (17.5%) children (chi-squared with Yates’ correction, p = 0.192), indicating no statistically significant overall impact of immunization on AD risk. Conclusions: The development of AD is primarily driven by hereditary predisposition and specific perinatal factors rather than by routine immunization. These findings confirm that neonatal BCG-M and HepB vaccination does not increase the risk of AD, providing a scientific basis to address vaccine hesitancy.
- 11 March 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (3) , 101-106
A Retrospective Cohort Study of Risk Factors for Symptomatic Venous Thromboembolism in Children and Adolescents With Lymphomas, Prognostic Tool Development, and Internal Prospective Validation
Venous thromboembolism (VTE) is a significant complication in pediatric lymphoma patients, but no validated risk stratification tool exists. In this single-center cohort study, patients aged 18 years or younger with lymphoma were included. A retrospective cohort (N=262) was analyzed for risk factors for symptomatic VTE (sVTE) and prognostic tool development, while a prospective cohort (N=128) was used for validation. sVTE occurred in 8% of the retrospective cohort. Independent risk factors included: mediastinal tumor volume ≥250 mL (OR=4.42, 95% CI: 1.62-12.7), patient transfer to an intensive care unit due to a life-threatening condition within 30 days of admission (ICU+) (OR=4.27, 95% CI: 1.25-13.9), age 12 years or older (OR=7.43, 95% CI: 2.21-34.6), non-O blood type (OR=5.13, 95% CI: 1.5-24.5). A scoring system assigned points as follows: age 12 years or older (1 point), mediastinal mass ≥250 mL (2 points), ICU+ (2 points), and non-O blood group (1 point). A score ≥2 identified high-risk patients (AUC 0.75, sensitivity 0.75, specificity 0.64). The 1-year cumulative incidence of sVTE was 3.9% (95% CI: 0%-8.2%) in non–high-risk versus 18.3% (95% CI: 7.5%-29.2%) in high-risk groups ( P =0.008). This validated prognostic tool effectively stratifies thrombosis risk and may guide prophylactic strategies in pediatric lymphoma.
- 11 March 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (3) , 101-106
A Retrospective Cohort Study of Risk Factors for Symptomatic Venous Thromboembolism in Children and Adolescents With Lymphomas, Prognostic Tool Development, and Internal Prospective Validation
Venous thromboembolism (VTE) is a significant complication in pediatric lymphoma patients, but no validated risk stratification tool exists. In this single-center cohort study, patients aged 18 years or younger with lymphoma were included. A retrospective cohort (N=262) was analyzed for risk factors for symptomatic VTE (sVTE) and prognostic tool development, while a prospective cohort (N=128) was used for validation. sVTE occurred in 8% of the retrospective cohort. Independent risk factors included: mediastinal tumor volume ≥250 mL (OR=4.42, 95% CI: 1.62-12.7), patient transfer to an intensive care unit due to a life-threatening condition within 30 days of admission (ICU+) (OR=4.27, 95% CI: 1.25-13.9), age 12 years or older (OR=7.43, 95% CI: 2.21-34.6), non-O blood type (OR=5.13, 95% CI: 1.5-24.5). A scoring system assigned points as follows: age 12 years or older (1 point), mediastinal mass ≥250 mL (2 points), ICU+ (2 points), and non-O blood group (1 point). A score ≥2 identified high-risk patients (AUC 0.75, sensitivity 0.75, specificity 0.64). The 1-year cumulative incidence of sVTE was 3.9% (95% CI: 0%-8.2%) in non–high-risk versus 18.3% (95% CI: 7.5%-29.2%) in high-risk groups ( P =0.008). This validated prognostic tool effectively stratifies thrombosis risk and may guide prophylactic strategies in pediatric lymphoma.
- 20 January 2026
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 22 (6) , 645-654
Evaluation of Dupilumab Therapy of Children with Multimorbid Atopic Phenotype: Preliminary Data from an Observational Study
Background. The genetically engineered biological drug dupilumab, which blocks the IL-4 and IL-13 signaling pathways, has demonstrated high efficacy in the treatment of Atopic Eczema (AE) in children and adults. However, there are no studies in Russia that evaluate the clinical response and the dynamics of biomarkers in children of different ages with a multimorbid atopic phenotype who receive therapy with this drug. The aim of the study is to evaluate the efficacy and safety of dupilumab, as well as to analyze the dynamics of inflammation biomarkers in children with a multimorbid atopic phenotype, including patients with moderate to severe AE. Methods. A prospective observational study included 15 children aged 6 months to 17 years 11 months. All patients received dupilumab for at least 16 weeks. Clinical efficacy was assessed using the SCORAD and EASI scales (with SCORAD-50/75/90 and EASI-50/75/90), quality of life (CDLQI), and control of concomitant diseases (ACT, VAS). Biomarkers (periostin, VEGF, DPP4, eosinophils, and FeNO) were determined before and 16 weeks after the start of therapy. Results. By the 16th week, all patients had reached SCORAD-50 and EASI-50, 80% had reached SCORAD-75, 100% had reached EASI-75, 60% had reached SCORAD-90, and 87% had reached EASI-90. During the treatment, there was a decrease in the levels of periostin (median change of –8%), VEGF (–9.7%), and a tendency towards a decrease in the number of eosinophils and FeNO, while the levels of DPP4 remained stable. The quality of life improved in most patients, and the accompanying manifestations (bronchial asthma, allergic rhinitis) were under full control. Side effects were limited to local reactions and conjunctivitis. Conclusion. Dupilumab therapy in children with a multimorbid atopic phenotype, including patients with moderate to severe AE, provides rapid and persistent clinical improvement, a decrease in the severity of inflammatory markers, and an improvement in quality of life. The data obtained confirm the efficacy and safety of the drug and indicate the prospects for using biomarkers to predict the individual response to therapy.
- 20 January 2026
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 22 (6) , 645-654
Evaluation of Dupilumab Therapy of Children with Multimorbid Atopic Phenotype: Preliminary Data from an Observational Study
Background. The genetically engineered biological drug dupilumab, which blocks the IL-4 and IL-13 signaling pathways, has demonstrated high efficacy in the treatment of Atopic Eczema (AE) in children and adults. However, there are no studies in Russia that evaluate the clinical response and the dynamics of biomarkers in children of different ages with a multimorbid atopic phenotype who receive therapy with this drug. The aim of the study is to evaluate the efficacy and safety of dupilumab, as well as to analyze the dynamics of inflammation biomarkers in children with a multimorbid atopic phenotype, including patients with moderate to severe AE. Methods. A prospective observational study included 15 children aged 6 months to 17 years 11 months. All patients received dupilumab for at least 16 weeks. Clinical efficacy was assessed using the SCORAD and EASI scales (with SCORAD-50/75/90 and EASI-50/75/90), quality of life (CDLQI), and control of concomitant diseases (ACT, VAS). Biomarkers (periostin, VEGF, DPP4, eosinophils, and FeNO) were determined before and 16 weeks after the start of therapy. Results. By the 16th week, all patients had reached SCORAD-50 and EASI-50, 80% had reached SCORAD-75, 100% had reached EASI-75, 60% had reached SCORAD-90, and 87% had reached EASI-90. During the treatment, there was a decrease in the levels of periostin (median change of –8%), VEGF (–9.7%), and a tendency towards a decrease in the number of eosinophils and FeNO, while the levels of DPP4 remained stable. The quality of life improved in most patients, and the accompanying manifestations (bronchial asthma, allergic rhinitis) were under full control. Side effects were limited to local reactions and conjunctivitis. Conclusion. Dupilumab therapy in children with a multimorbid atopic phenotype, including patients with moderate to severe AE, provides rapid and persistent clinical improvement, a decrease in the severity of inflammatory markers, and an improvement in quality of life. The data obtained confirm the efficacy and safety of the drug and indicate the prospects for using biomarkers to predict the individual response to therapy.
- Open Access
- 14 January 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (4) , 11-26
Hepatocellular carcinoma in children and adolescents: results of a retrospective analysis
Hepatocellular carcinoma (HCC) is a rare primary liver malignancy in children and adolescents with poor prognosis. The aim of the study – to evaluate the clinical characteristics, treatment strategies, and outcomes in pediatric and adolescent patients with HCC, and to identify factors influencing survival. Materials and methods . A retrospective analysis was conducted on 39 patients aged 4 to 16 years with histologically confirmed HCC treated and consulted at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology between 2012 and 2023. Demographic and clinical features, underlying predisposing conditions, laboratory findings, intrahepatic tumor spread (PRETEXT staging), surgical interventions, and systemic treatment regimens were analyzed. Results. Median age was 133.5 months (11.1 years; range 49.7–199.4 months). Male to female ratio was 1.1:1. HCC developed de novo in 77 % of patients, while 23 % had predisposing conditions – most commonly chronic hepatitis B. The clinical presentation was predominantly non-specific, and in 28.9 % of cases, the tumor was discovered incidentally. Serum alpha-fetoprotein levels were within normal limits in 45% of patients, particularly in those with fibrolamellar HCC. Advanced intrahepatic tumor spread (PRETEXT stage III–IV) was observed in 60 % of cases, and distant metastases were present in 18 % of patients. The 5-year overall survival (OS) was 37 %, and the event-free survival was 26 %. The presence of distant metastases was significantly associated with inferior outcomes (5-year OS: 45 % in non-metastatic vs. 0 % in metastatic cases, p < 0.001). PRETEXT stage and histological subtype showed no significant impact on OS or event-free survival. Surgical treatment (hepatic resection or orthotopic liver transplantation) was performed in 66 % of patients and was significantly associated with improved outcomes: 5-year OS was 54 % in the surgical group versus 0 % in those who did not undergo surgery (p < 0.001). Liver transplantation showed a trend toward better outcomes compared to resection, although the difference was not statistically significant. Initial treatment strategy (primary resection vs. biopsy with neoadjuvant chemotherapy) had no impact on survival. Conclusion s. Pediatric HCC is a rare but highly aggressive malignancy that is often diagnosed at an advanced stage. Radical surgical resection, including liver transplantation in certain cases, remains the primary determinant of prognosis. Improved outcomes require early diagnosis, early discussion of therapeutic tactics in center specialized in hepatobiliary surgery and inclusion of pediatric patients in multicenter clinical trials.
- 14 January 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (4) , 11-26
Open AccessHepatocellular carcinoma in children and adolescents: results of a retrospective analysis
Hepatocellular carcinoma (HCC) is a rare primary liver malignancy in children and adolescents with poor prognosis. The aim of the study – to evaluate the clinical characteristics, treatment strategies, and outcomes in pediatric and adolescent patients with HCC, and to identify factors influencing survival. Materials and methods . A retrospective analysis was conducted on 39 patients aged 4 to 16 years with histologically confirmed HCC treated and consulted at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology between 2012 and 2023. Demographic and clinical features, underlying predisposing conditions, laboratory findings, intrahepatic tumor spread (PRETEXT staging), surgical interventions, and systemic treatment regimens were analyzed. Results. Median age was 133.5 months (11.1 years; range 49.7–199.4 months). Male to female ratio was 1.1:1. HCC developed de novo in 77 % of patients, while 23 % had predisposing conditions – most commonly chronic hepatitis B. The clinical presentation was predominantly non-specific, and in 28.9 % of cases, the tumor was discovered incidentally. Serum alpha-fetoprotein levels were within normal limits in 45% of patients, particularly in those with fibrolamellar HCC. Advanced intrahepatic tumor spread (PRETEXT stage III–IV) was observed in 60 % of cases, and distant metastases were present in 18 % of patients. The 5-year overall survival (OS) was 37 %, and the event-free survival was 26 %. The presence of distant metastases was significantly associated with inferior outcomes (5-year OS: 45 % in non-metastatic vs. 0 % in metastatic cases, p < 0.001). PRETEXT stage and histological subtype showed no significant impact on OS or event-free survival. Surgical treatment (hepatic resection or orthotopic liver transplantation) was performed in 66 % of patients and was significantly associated with improved outcomes: 5-year OS was 54 % in the surgical group versus 0 % in those who did not undergo surgery (p < 0.001). Liver transplantation showed a trend toward better outcomes compared to resection, although the difference was not statistically significant. Initial treatment strategy (primary resection vs. biopsy with neoadjuvant chemotherapy) had no impact on survival. Conclusion s. Pediatric HCC is a rare but highly aggressive malignancy that is often diagnosed at an advanced stage. Radical surgical resection, including liver transplantation in certain cases, remains the primary determinant of prognosis. Improved outcomes require early diagnosis, early discussion of therapeutic tactics in center specialized in hepatobiliary surgery and inclusion of pediatric patients in multicenter clinical trials.
- Open Access
- 13 March 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (1) , 51-61
Pathogen-reduced red blood cell suspension in pediatric transfusion practice
Introduction. Pathogen reduction technologies in donor blood products have provided a preventive approach against a variety of hemotransmissive infections as well as prevention of donor leukocyte complications. However, while pathogen reduction in plasma and platelet concentrates is currently widespread, methods for reducing pathogens in red blood cell (RBC)-containing products are still being studied.Aim: to analyze the transfusion results of a pathogen-reduced RBC suspension in patients with various oncological and hematological diseases as well as defects of the immune system in order to prevent transfusion transmission of cytomegalovirus infection.Patients and methods. The results of transfusion therapy of a pathogen-reduced RBC suspension for the prevention of transfusion transmission of CMV infection in 27 patients who underwent transfusions during a long follow-up period are presented.Results. A total of 27 patients received 167 transfusions of pathogen-reduced RBC suspension. Transfusion efficacy, assessed by hemoglobin increase, was dependent on the transfusion volume per body weight, but was independent of the storage time of the RBC suspension over the measured interval. The transfusions were effective and tolerated without complications.Conclusion. The clinical use of pathogen-reduced RBC suspension is safe and provides sufficient clinical and laboratory efficacy.
- 13 March 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (1) , 51-61
Open AccessPathogen-reduced red blood cell suspension in pediatric transfusion practice
Introduction. Pathogen reduction technologies in donor blood products have provided a preventive approach against a variety of hemotransmissive infections as well as prevention of donor leukocyte complications. However, while pathogen reduction in plasma and platelet concentrates is currently widespread, methods for reducing pathogens in red blood cell (RBC)-containing products are still being studied.Aim: to analyze the transfusion results of a pathogen-reduced RBC suspension in patients with various oncological and hematological diseases as well as defects of the immune system in order to prevent transfusion transmission of cytomegalovirus infection.Patients and methods. The results of transfusion therapy of a pathogen-reduced RBC suspension for the prevention of transfusion transmission of CMV infection in 27 patients who underwent transfusions during a long follow-up period are presented.Results. A total of 27 patients received 167 transfusions of pathogen-reduced RBC suspension. Transfusion efficacy, assessed by hemoglobin increase, was dependent on the transfusion volume per body weight, but was independent of the storage time of the RBC suspension over the measured interval. The transfusions were effective and tolerated without complications.Conclusion. The clinical use of pathogen-reduced RBC suspension is safe and provides sufficient clinical and laboratory efficacy.
- Open Access
- 19 November 2024
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 21 (5) , 417-431
The Prevalence of Sensitization to Food Allergens from the Group of “Big Eight” in Children with Atopic Phenotype: Cross-Sectional Study
Background. Food allergy (FA) is a common chronic disease. There are no official data on the prevalence of FA in Russia. The results of only a few Russian studies of FA and anaphylaxis in children have been published.The aim of the study is to study the prevalence of sensitization to food allergens from the group of “big eight” in children with atopic phenotype living in the Moscow agglomeration.Methods. The cross-sectional study included children aged 0 to 17 years with complaints of seasonal manifestations of allergies / diagnosed with seasonal allergic rhinitis (pollinosis); with complaints of allergic reactions when eating any food; with complaints of atopic dermatitis. The determination of sensitization to allergens was carried out using ImmunoCAP technology, ImmunoCAP ISAC / ALEX2 allergy chips.Results. 240 children were included in the study. Sensitization to extracts of food allergens of the “big eight”, detected by the ImmunoCAP monoplex method, was determined in 1.5 (for fish) — 5 (for wheat) several times more often than with multiplex allergodiagnostics. In molecular allergodiagnosis, sensitization to hazelnut allergens was found in 57%, peanuts — in 47%, soy — in 39%, walnut — in 24%, chicken egg — in 18%, cow’s milk — in 12%, fish — in 9.7%, cashews — in 7.6%, shrimp — in 6.3%, wheat — in 4.6% of children. The frequency of food allergy symptoms, based on the assessment of the patients’ parents, was up to 7 times higher than the detected frequency of sensitization, accompanied by complaints of symptoms when eating the appropriate foods. Among the products causing symptoms in such patients, hazelnuts, cow’s milk, chicken egg and peanuts were in the lead.Conclusion. More than half of Russian children are sensitized to the allergens of the “big eight”, while clinically significant sensitization was noted 2 times less often. Sensitization to the allergen components of the PR-10 group of hazelnuts, peanuts and soybeans was most often detected. The frequency of FA diagnosed by a doctor is significantly lower than the frequency of the disease detected by the results of a survey of patients’ parents.
- 19 November 2024
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 21 (5) , 417-431
Open AccessThe Prevalence of Sensitization to Food Allergens from the Group of “Big Eight” in Children with Atopic Phenotype: Cross-Sectional Study
Background. Food allergy (FA) is a common chronic disease. There are no official data on the prevalence of FA in Russia. The results of only a few Russian studies of FA and anaphylaxis in children have been published.The aim of the study is to study the prevalence of sensitization to food allergens from the group of “big eight” in children with atopic phenotype living in the Moscow agglomeration.Methods. The cross-sectional study included children aged 0 to 17 years with complaints of seasonal manifestations of allergies / diagnosed with seasonal allergic rhinitis (pollinosis); with complaints of allergic reactions when eating any food; with complaints of atopic dermatitis. The determination of sensitization to allergens was carried out using ImmunoCAP technology, ImmunoCAP ISAC / ALEX2 allergy chips.Results. 240 children were included in the study. Sensitization to extracts of food allergens of the “big eight”, detected by the ImmunoCAP monoplex method, was determined in 1.5 (for fish) — 5 (for wheat) several times more often than with multiplex allergodiagnostics. In molecular allergodiagnosis, sensitization to hazelnut allergens was found in 57%, peanuts — in 47%, soy — in 39%, walnut — in 24%, chicken egg — in 18%, cow’s milk — in 12%, fish — in 9.7%, cashews — in 7.6%, shrimp — in 6.3%, wheat — in 4.6% of children. The frequency of food allergy symptoms, based on the assessment of the patients’ parents, was up to 7 times higher than the detected frequency of sensitization, accompanied by complaints of symptoms when eating the appropriate foods. Among the products causing symptoms in such patients, hazelnuts, cow’s milk, chicken egg and peanuts were in the lead.Conclusion. More than half of Russian children are sensitized to the allergens of the “big eight”, while clinically significant sensitization was noted 2 times less often. Sensitization to the allergen components of the PR-10 group of hazelnuts, peanuts and soybeans was most often detected. The frequency of FA diagnosed by a doctor is significantly lower than the frequency of the disease detected by the results of a survey of patients’ parents.
- Open Access
- 15 October 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (3) , 130-137
Post-thrombotic syndrome in children with symptomatic deep vein thrombosis
Deep vein thrombosis (DVT) is an increasingly common diagnosis in pediatric inpatients. Approximately 85% of DVTs of extremities are associated with the use of a central venous catheter (CVC). CVC-related thrombosis and non-CVC-related thrombosis differ in their pathophysiology and patient characteristics. We thought it worthwhile to try and analyze whether there was an association between these parameters and further development of complications, namely, post-thrombotic syndrome (PTS). Thus, we aimed to evaluate differences in patient characteristics as well as in the frequency and severity of PTS in children with symptomatic CVC-related and non-CVC-related thrombosis. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. We retrospectively analyzed medical records of patients aged 0 to 18 years (at the time of thrombosis) who had undergone treatment at the Center between 2013 and 2023 and selected patients with verified symptomatic DVT of the upper or lower extremity. The patients were divided into 2 groups: patients with CVC-related thrombosis (group 1) and patients with non-CVC-related thrombosis (group 2). Then we analyzed data on PTS in these patients collected during consultations with a hematologist at the Center or via a phone interview. PTS was evaluated using the Russian versions of the Manco–Johnson Instrument (MJI), the Modified Villalta Scale (MVS) and the Clinical Assessment of PTS (CAPTSure) (see the supplementary materials). The statistical significance of differences between the groups was assessed using Chi-square test or, if the expected values in a table were less than 5, using Fisher’s exact test. The study included 47 patients with symptomatic DVT: 17 patients with CVC-related DVT and 30 patients with non-CVCrelated DVT. The patients with CVC-related DVT were found to be younger at the time of thrombosis (median age: 4.1 years (range: 0–17 years) in group 1 versus 15.5 years (range: 3–17 years) in group 2; р < 0.001) and were followed up for longer periods of time (median follow-up time: 5 years (range: 0.5–15 years) in group 1 versus 1 year (range: 0.5–7.5 years) in group 2; р = 0.001). Recanalization at 3 months after DVT was better in the patients with non-CVC-related DVT (50% of the patients in group 1 versus 93% of the patients in group 2; р = 0.002). The overall frequency of PTS was 87% in accordance with MVS/ MJI and 68% as per CAPTSure. The frequency of PTS in the groups was comparable: there were 13 (76%) patients with PTS in the CVC-related thrombosis group and 28 (93%) patients in the non-CVC-related thrombosis group; р = 0.2). The patients with non-CVC-related DVT were found to have more severe PTS more often: 44% of the patients with moderate PTS in the non-CVCrelated DVT group versus 23% of the patients with moderate PTS and CVC-related DVT; р = 0.2. However, these differences did not turn out to be statistically significant. Thus, there were no statistically significant differences in either the frequency or severity of PTS between the two groups. In this study, the overall frequency of PTS in the patients with symptomatic DVT was rather high but the majority of the children in both groups had mild PTS. Still, since PTS is a late complication, it is important to continue patient follow-up to monitor symptoms and severity of chronic venous insufficiency over time.
- 15 October 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (3) , 130-137
Open AccessPost-thrombotic syndrome in children with symptomatic deep vein thrombosis
Deep vein thrombosis (DVT) is an increasingly common diagnosis in pediatric inpatients. Approximately 85% of DVTs of extremities are associated with the use of a central venous catheter (CVC). CVC-related thrombosis and non-CVC-related thrombosis differ in their pathophysiology and patient characteristics. We thought it worthwhile to try and analyze whether there was an association between these parameters and further development of complications, namely, post-thrombotic syndrome (PTS). Thus, we aimed to evaluate differences in patient characteristics as well as in the frequency and severity of PTS in children with symptomatic CVC-related and non-CVC-related thrombosis. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. We retrospectively analyzed medical records of patients aged 0 to 18 years (at the time of thrombosis) who had undergone treatment at the Center between 2013 and 2023 and selected patients with verified symptomatic DVT of the upper or lower extremity. The patients were divided into 2 groups: patients with CVC-related thrombosis (group 1) and patients with non-CVC-related thrombosis (group 2). Then we analyzed data on PTS in these patients collected during consultations with a hematologist at the Center or via a phone interview. PTS was evaluated using the Russian versions of the Manco–Johnson Instrument (MJI), the Modified Villalta Scale (MVS) and the Clinical Assessment of PTS (CAPTSure) (see the supplementary materials). The statistical significance of differences between the groups was assessed using Chi-square test or, if the expected values in a table were less than 5, using Fisher’s exact test. The study included 47 patients with symptomatic DVT: 17 patients with CVC-related DVT and 30 patients with non-CVCrelated DVT. The patients with CVC-related DVT were found to be younger at the time of thrombosis (median age: 4.1 years (range: 0–17 years) in group 1 versus 15.5 years (range: 3–17 years) in group 2; р < 0.001) and were followed up for longer periods of time (median follow-up time: 5 years (range: 0.5–15 years) in group 1 versus 1 year (range: 0.5–7.5 years) in group 2; р = 0.001). Recanalization at 3 months after DVT was better in the patients with non-CVC-related DVT (50% of the patients in group 1 versus 93% of the patients in group 2; р = 0.002). The overall frequency of PTS was 87% in accordance with MVS/ MJI and 68% as per CAPTSure. The frequency of PTS in the groups was comparable: there were 13 (76%) patients with PTS in the CVC-related thrombosis group and 28 (93%) patients in the non-CVC-related thrombosis group; р = 0.2). The patients with non-CVC-related DVT were found to have more severe PTS more often: 44% of the patients with moderate PTS in the non-CVCrelated DVT group versus 23% of the patients with moderate PTS and CVC-related DVT; р = 0.2. However, these differences did not turn out to be statistically significant. Thus, there were no statistically significant differences in either the frequency or severity of PTS between the two groups. In this study, the overall frequency of PTS in the patients with symptomatic DVT was rather high but the majority of the children in both groups had mild PTS. Still, since PTS is a late complication, it is important to continue patient follow-up to monitor symptoms and severity of chronic venous insufficiency over time.
- Open Access
- 9 August 2024
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (2) , 21-27
Long-term consequence of asymptomatic thrombosis in children
Introduction. Over the past 10 years, there has been a 130 % increase in the amount of thrombosis in hospitalized children. The data about frequency, outcomes and long-term complications of incidental thrombosis is usually presented together with symptomatic thrombosis, and the problem of asymptomatic thrombosis seems to be underestimated.Aim to the study – to assess the patient-related characteristics, outcomes of incidental thrombosis in children. To estimate the frequency, severity and risk factors of post-thrombotic syndrome (PTS) after incidental thrombosis. To evaluate the effect of therapy on thrombus resolution and frequency of PTS following asymptomatic deep vein thrombosis (DVT) in children.Materials and methods. We have retrospectively analyzed the medical records of 48 patients from 0 to 17 years (at the time of thrombosis) from 2013 to 2023 of our tertiary care Centre with objectively confirmed asymptomatic DVT of upper or lower extremity. All patients were divided into 2 groups: patients, who did not receive antithrombotic treatment (G1) and who assessed therapy (G2). Then we analyzed the data of PTS assessment in these patients. PTS was measured using Manco–Jonson Instrument (MJI), Modified Villalta Scale (MVS), the Clinical Assessment of Post-Thrombotic Syndrome (CAPTSure). Chi-square test was used to assess the statistical significance of differences between groups.Results. 90 % of patients were cancer patients, most of DVTs (96 %) were in the veins of upper extremity, 27 % of thrombosis were occlusive. There were no statistically significant differences between G1 and G2 in thrombus resolution, severity and frequency of PTS. The overall frequency of PTS was 46 % using MVS/MJI and 29 % using CAPTSure. Majority of children had mild PTS, the most common symptom was the presence of collaterals. There was 1 patient with moderate PTS in G2.Conclusion. The overall frequency of PTS in patients with asymptomatic thrombosis was 46 %. However, most patients had mild PTS and slight clinical sings. There were no statistically significant difference in the rate of recanalization at 3 months after thrombosis between patients who received anticoagulant therapy and those who did not. Also, there were no statistically significant differences in the frequency and severity of PTS between groups.
- 9 August 2024
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (2) , 21-27
Open AccessLong-term consequence of asymptomatic thrombosis in children
Introduction. Over the past 10 years, there has been a 130 % increase in the amount of thrombosis in hospitalized children. The data about frequency, outcomes and long-term complications of incidental thrombosis is usually presented together with symptomatic thrombosis, and the problem of asymptomatic thrombosis seems to be underestimated.Aim to the study – to assess the patient-related characteristics, outcomes of incidental thrombosis in children. To estimate the frequency, severity and risk factors of post-thrombotic syndrome (PTS) after incidental thrombosis. To evaluate the effect of therapy on thrombus resolution and frequency of PTS following asymptomatic deep vein thrombosis (DVT) in children.Materials and methods. We have retrospectively analyzed the medical records of 48 patients from 0 to 17 years (at the time of thrombosis) from 2013 to 2023 of our tertiary care Centre with objectively confirmed asymptomatic DVT of upper or lower extremity. All patients were divided into 2 groups: patients, who did not receive antithrombotic treatment (G1) and who assessed therapy (G2). Then we analyzed the data of PTS assessment in these patients. PTS was measured using Manco–Jonson Instrument (MJI), Modified Villalta Scale (MVS), the Clinical Assessment of Post-Thrombotic Syndrome (CAPTSure). Chi-square test was used to assess the statistical significance of differences between groups.Results. 90 % of patients were cancer patients, most of DVTs (96 %) were in the veins of upper extremity, 27 % of thrombosis were occlusive. There were no statistically significant differences between G1 and G2 in thrombus resolution, severity and frequency of PTS. The overall frequency of PTS was 46 % using MVS/MJI and 29 % using CAPTSure. Majority of children had mild PTS, the most common symptom was the presence of collaterals. There was 1 patient with moderate PTS in G2.Conclusion. The overall frequency of PTS in patients with asymptomatic thrombosis was 46 %. However, most patients had mild PTS and slight clinical sings. There were no statistically significant difference in the rate of recanalization at 3 months after thrombosis between patients who received anticoagulant therapy and those who did not. Also, there were no statistically significant differences in the frequency and severity of PTS between groups.